Cidara Therapeutics, Inc.: M&A transaction — Merck completes acquisition of Cidara Therapeutics for $221.50 per share

Cidara Therapeutics, Inc.

Tender offer expired Jan 6 with 27,149,333 common shares and 89,956 Series A shares validly tendered, representing ~88.3% of total voting shares.
Each common share converted to $221.50 cash; each Series A share converted to $15,505.00 cash, without interest.
Common shares delisted from Nasdaq effective Jan 7; company will file Form 15 to terminate SEC registration and reporting obligations.
Board replaced by Merck designees Jon Filderman, Melissa Leonard, Dalton Smart; prior directors resigned.
Company's equity incentive plans and stock purchase plan terminated at the Effective Time.

item 1.02 item 2.01 item 3.01 item 3.03 item 5.01 item 5.02 item 5.03 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Cidara Therapeutics, Inc.: Amended and restated certificate of incorporation and bylaws in connection with merger.

Change: bylaw amendment

Exact text from the filing

Pursuant to the terms of the Merger Agreement, at the Effective Time, the Company’s amended and restated certificate of incorporation, as amended, and amended and restated bylaws were amended and restated in their entirety in the forms filed as Exhibits 3.1 and 3.2, respectively, to this Current Report on Form 8-K, and are incorporated herein by reference.

View on SEC.gov

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.99

Cidara Therapeutics, Inc. underwent a change of control involving Merck Sharp & Dohme LLC for $221.50 per Common Share in cash and $15,505.00 per Series A Convertible Voting Preferred Share in cash (closed 2026-01-07).

Action: change of control
Counterparty: Merck Sharp & Dohme LLC
Consideration: $221.50 per Common Share in cash and $15,505.00 per Series A Convertible Voting Preferred Share in cash
Closing: 2026-01-07

Exact text from the filing

5, 2025, Purchaser commenced a tender offer to acquire (i) all of the outstanding shares of common stock of the Company, par value $0.0001 per share (the “ Common Shares ”), for $221.50 per Common Share (the “ Common Share Offer Price ”) and (ii) all of the outstanding shares of Series A Convertible Voting Preferred Stock of the Company, par value $0.0001 per

View on SEC.gov

Browse all governance changes →

Source: SEC EDGAR

accession 0001193125-26-005517

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.